Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 218 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2016, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 11, 7, 32, 13 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 7 molecules, respectively for Clostridium difficile Infections.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 6
Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview 7
Therapeutics Development 8
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Development by Companies 10
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes 13
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Products Glance 14
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Development by Companies 18
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Investigation by Universities/Institutes 23
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development 24
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment 74
Drug Profiles 84
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects 194
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products 197
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones 198
Appendix 208

List of Tables

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2016 17
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Development by Companies, H2 2016 (Contd..1) 20
Number of Products under Development by Companies, H2 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Development, H2 2016 25
Comparative Analysis by Unknown Stage Development, H2 2016 26
Products under Development by Companies, H2 2016 27
Products under Development by Companies, H2 2016 (Contd..1) 28
Products under Development by Companies, H2 2016 (Contd..2) 29
Products under Development by Companies, H2 2016 (Contd..3) 30
Products under Development by Companies, H2 2016 (Contd..4) 31
Products under Investigation by Universities/Institutes, H2 2016 32
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H2 2016 33
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H2 2016 34
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H2 2016 35
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H2 2016 36
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Limited, H2 2016 37
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H2 2016 38
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Angothera GmbH, H2 2016 39
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Antibiotx ApS, H2 2016 40
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H2 2016 41
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H2 2016 42
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp., H2 2016 43
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3 Jian, Inc, H2 2016 44
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corporation, H2 2016 45
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone, Inc., H2 2016 46
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra, H2 2016 47
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 48
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by e-Therapeutics Plc, H2 2016 49
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec, Inc., H2 2016 50
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc., H2 2016 51
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H2 2016 52
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Limited, H2 2016 53
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 54
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 55
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MedImmune, LLC, H2 2016 56
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co., Inc., H2 2016 57
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H2 2016 58
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix, Inc., H2 2016 59
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Limited, H2 2016 60
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016 61
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Morphochem AG, H2 2016 62
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H2 2016 63
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Limited, H2 2016 64
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 65
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics, Inc., H2 2016 66
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 67
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc., H2 2016 68
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Procarta Biosystems Limited, H2 2016 69
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Limited, H2 2016 70
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc., H2 2016 71
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H2 2016 72
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome, Inc., H2 2016 73
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H2 2016 74
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2016 75
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H2 2016 76
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H2 2016 77
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H2 2016 78
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Limited, H2 2016 79
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H2 2016 80
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Venenum Biodesign, L.L.C, H2 2016 81
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H2 2016 82
Assessment by Monotherapy Products, H2 2016 83
Assessment by Combination Products, H2 2016 84
Number of Products by Stage and Target, H2 2016 86
Number of Products by Stage and Mechanism of Action, H2 2016 88
Number of Products by Stage and Route of Administration, H2 2016 90
Number of Products by Stage and Molecule Type, H2 2016 92
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2016 203
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..1), H2 2016 204
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..2), H2 2016 205
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H2 2016 206